The effect of tryptophan administration on fatty acid synthesis in the livers of rats under various nutritional conditions.
1. Tryptophan was administered to rats under various nutritional conditions: fasted for 24 hr, fasted and refed with glucose or corn-oil, fasted and administered glycerol intramuscularly, and nonfasted. 2. The changes in the contents of glycolytic intermediates in the livers indicated that the phosphoenolpyruvate carboxykinase [EC 4.1.1.32] reaction is inhibited by tryptophan administration in all groups of rats. The inversely related changes in the contents of malate and phosphoenolpyruvate were associated with the accumulation of quinolinate in the livers. The content of quinolinate which exhibited the half-maximal effect on the contents of both metabolites was 0.1-0.2 mumole per g liver. 3. The rate of incorporation of 3H from 3H2O into the total hepatic fatty acids was increased about 2-fold by the administration of this amino acid to the fasted rats. The enhancement of the rate was closely related to the increase in the citrate content. The hyperlipogenesis was also related to the decrease of acetyl-CoA and the increase of malonyl-CoA. The content of long-chain acyl-CoA was not affected. These effects of tryptophan administration on the hepatic fatty acid metabolism were found in all groups of rats. The liver content of glycerol 3-phosphate was decreased by tryptophan administration was markedly increased by glycerol injection. The injection of glycerol into the control and the tryptophan-treated rats produced a marked increase of glycerol 3-phosphate but did not affect the rate of fatty acid synthesis in the livers of either group. 4. It may be concluded that, in the livers of rats under various nutritional conditions, the short-term control of fatty acid synthesis by tryptophan administration is most likely due to the activation of acetyl-coenzyme A carboxylase [EC 6.4.1.2] by citrate.
D000105:Acetyl Coenzyme A / Q000378:metabolism; D000103:Acetyl-CoA Carboxylase / Q000378:metabolism; D000818:Animals; D050260:Carbohydrate Metabolism; D002951:Citrates / Q000378:metabolism; D004789:Enzyme Activation / Q000187:drug effects; D005215:Fasting; D005227:Fatty Acids / Q000096:biosynthesis*; D005636:Fructosephosphates / Q000378:metabolism; D005943:Gluconeogenesis / Q000187:drug effects; D005990:Glycerol / Q000494:pharmacology; D005994:Glycerophosphates / Q000378:metabolism; D007657:Ketone Bodies / Q000378:metabolism; D007773:Lactates / Q000378:metabolism; D008099:Liver / Q000201:enzymology / Q000378:metabolism*; D008293:Malates / Q000378:metabolism; D008297:Male; D008314:Malonates / Q000378:metabolism; D010729:Phosphoenolpyruvate Carboxykinase (GTP) / Q000378:metabolism; D011805:Quinolinic Acids / Q000378:metabolism; D051381:Rats; D014364:Tryptophan / Q000008:administration & dosage / Q000494:pharmacology*
D002951:Citrates; D005227:Fatty Acids; D005636:Fructosephosphates; D005994:Glycerophosphates; D007657:Ketone Bodies; D007773:Lactates; D008293:Malates; D008314:Malonates; D011805:Quinolinic Acids; D000105:Acetyl Coenzyme A; D014364:Tryptophan; D010729:Phosphoenolpyruvate Carboxykinase (GTP); D000103:Acetyl-CoA Carboxylase; D005990:Glycerol